Exploiting our knowledge of NF-κB signaling for the treatment of mammary cancer
Exploiting our knowledge of NF-κB signaling for the treatment of mammary cancer
复制标题
DOI：
10.1007/s10911-006-9013-5
复制
发表时间：
2006-01-01
影响因子：
2.5
通讯作者：
Doppler, Wolfgang
中科院分区：
文献类型：
--
作者：
Haffner, Michael C.;Berlato, Chiara;Doppler, Wolfgang
核因子-kappaB (NF-kappa B) 与乳腺小叶肺泡发育有关。在乳腺癌中，它的激活通过刺激细胞增殖、促存活、血管生成途径和转移与肿瘤进展相关。免疫系统中 NF-κ B 的激活是否会影响乳腺癌仍不清楚。除了乳腺癌组织中常见的组成型激活之外，用于治疗乳腺癌的放射治疗剂和化疗剂还可导致 NF-κ B 的激活。据推测，这种效应有助于对这些药物产生耐药性，并建议使用 NF-κ B 抑制剂作为治疗的敏化剂。该综述描述了用于抑制 NF-κ B 功能的主要靶点和药物，并讨论了使用这些抑制剂治疗乳腺癌的未来前景。
Nuclear Factor-kappaB (NF-kappa B) has been implicated in the lobuloalveolar development of the mammary gland. In breast cancer its activation has been linked to tumor progression via stimulation of cell proliferation, prosurvival, and angiogenesis pathways and metastasis. Whether NF-kappa B activation in the immune system influences mammary cancer remains unclear. In addition to the constitutive activation frequently found in mammary carcinoma tissue, radio- and chemotherapeutic agents used in the treatment of mammary cancer can lead to activation of NF-kappa B. This effect has been postulated to contribute to the development of resistance to these agents and suggests the use of NF-kappa B inhibitors as sensitizers for therapy. The review describes principle targets and drugs used to inhibit NF-kappa B function and discusses future perspectives in the use of these inhibitors for the treatment of mammary cancer.